Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Biologic DMARD----[2] 46, 271
2Biologic DMARDs----[1] 107
3Biological DMARDs----[2] 86, 107
4Classic DMARDs treatment group----[1] 46
5Co-medication: Synthetic DMARDs----[1] 46
6Combination of DMARDs----[1] 107
7Conventional DMARD combination----[1] 46
8Conventional DMARDs----[1] 46
9Conventional Synthetic DMARD----[1] 46
10Disease-modifying antirheumatic drugs (DMARDs)----[1] 46
11DMARD----[1] 46
12DMARD cessation----[1] 46
13DMARD maintenance----[1] 46
14DMARD Therapy----[1] 46
15DMARDS----[2] 46, 271
16DMARDs (disease-modifying antirheumatic drugs)----[1] 46
17DMARDs (methotrexate[1] Methotrexate[1] D00142 [2] DHFR,
DHFR2 💬		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46
18DMARDs or Biologics----[1] 46
19Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc[1] Etanercept[1] D00742 [2] LTA,
TNF 💬		[67] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 46
20HUC-MSC + DMARDs----[1] 46
21Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)----[1] 46
22Non-Biologic DMARDs----[3] 46, 86, 107
23Non-biological DMARDs----[1] 46
24Nonbiologic DMARDs of investigator's choice----[1] 46
25Patient treated with DMARD----[1] 46
26Permitted DMARDs----[1] 46
27Phase 1: Conventiaonal DMARD----[1] 46
28Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)----[1] 46
29Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)----[1] 46
30Synthetic DMARD(s)----[1] 46
31Targeted synthetic DMARD class----[1] 46
32Therapy with disease-modifying anti rheumatic drugs (DMARD)----[1] 46
33TNF-a antagonists, non-TNFs, DMARD non-biologics----[2] 46, 271
34Trivalent chromium versus synthetic and/ or biological DMARDs[1] Chromium---[1] 46
35UC-MSC+DMARDS----[1] 46